Cytokinetics (CYTK) Q4 2025 earnings summary

Executive summary

• Achieved FDA, China NMPA, and European Commission approvals for MYQORZO in obstructive HCM, with U.S. launch underway and Germany launch planned for Q2 2026.

• Transitioned to a global commercial-stage company, launching MYQORZO in the U.S. and preparing for European rollout.

• Strong initial demand and engagement from healthcare providers, with over 700 HCPs REMS certified within three weeks and positive early feedback.

• Advanced clinical pipeline with key readouts and regulatory milestones expected in 2026, including MAPLE-HCM sNDA submission and pivotal trials for aficamten, omecamtiv mecarbil, and ulacamten.

• Ended 2025 with $1.22 billion in cash, cash equivalents, and investments, supporting commercial and R&D activities.

Financial highlights

• Q4 2025 revenues were $17.8 million, up from $16.9 million in Q4 2024; full-year 2025 revenues reached $88 million, up from $18.5 million in 2024, driven by technology transfer and milestone payments.

• Full-year 2025 revenues benefited from a $52.4 million technology transfer to Bayer and $15 million in milestone payments from Sanofi.

• R&D expenses for 2025 were $416 million, up from $339.4 million in 2024; Q4 2025 R&D expenses were $104.4 million, including $14.2 million stock-based compensation.

• G&A expenses for 2025 rose to $284.3 million from $215.3 million; Q4 2025 G&A expenses were $91.7 million, including $16.3 million stock-based compensation.

• Net loss for 2025 was $785 million ($6.54/share), compared to $589.5 million ($5.26/share) in 2024; Q4 2025 net loss was $183 million ($1.50/share).

Outlook and guidance

• No product sales guidance for MYQORZO in 2026 due to early launch stage.

• 2026 GAAP combined R&D and SG&A expense guidance: $830–$870 million, including $120–$130 million in non-cash stock-based compensation; excluding stock-based compensation, $700–$750 million.

• Capital allocation priorities: U.S. and EU MYQORZO launches, pipeline advancement, and muscle biology platform investment.

• Key 2026 milestones: ACACIA-HCM top-line results, MYQORZO Germany launch, MAPLE-HCM sNDA FDA decision, and ongoing clinical trial progress.